Bavencio Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Avelumab

Indications/Uses

Monotherapy for metastatic Merkel cell carcinoma. 1st-line maintenance treatment of patients w/ locally advanced or metastatic urothelial carcinoma whose disease has not progressed w/ 1st-line platinum-based induction chemotherapy. 1st-line treatment of adult patients w/ advanced renal cell carcinoma in combination w/ axitinib.

Dosage/Direction for Use

IV Monotherapy: 800 mg infusion over 60 min every 2 wk. Combination therapy: 800 mg infusion over 60 min every 2 wk & axitinib 5 mg PO bd (12 hr apart) w/ or w/o food until disease progression or unacceptable toxicity. Premed: Antihistamine & paracetamol prior to the 1st 4 infusions.

MIMS Class

Cancer Immunotherapy

ATC Classification

L01FF04 - avelumab ; Belongs to the class of PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Bavencio conc for soln for infusion 200 mg/10 mL

Packing/Price

1's

Bavencio

avelumab

Manufacturer:

Merck Serono SA (Aubonne)